Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

A binding mode landscape for disordered protein interactions. by Attila Horvath (285787)

“…Context-dependent <b>disorder-to-order</b> binding is exemplified by the <b>polymorphic interactions</b> of the ribosomal S6 kinase 1 (RSK1, residues 697–703, <i>light blue dots</i>), which adopts different secondary structures upon binding to S100B, corresponding to autoinhibited and active forms (PDB:5csf, 5csi, 5csj [<a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1007864#pcbi.1007864.ref023" target="_blank">23</a>]). …”

Effect of MMP9 on phFAK and ILK expression. by Nabila Djaziri (17537499)

“…<p>(A, B) Comparative phFAK expression in jck-MMP9+/+ and jck-MMP9-/- kidneys. …”

A story about oxygen nanobubbles (RNS60) by Jorge H Ramirez (587826)

“…In addition, Revalesio states that RNS60 decrease muscle fatigue and improve exercise performance.[6]</p> <p>Reliant Water is a sport beverage produced by Revalesio and available to the public at the price of $100 USD per 32 bottles. …”

Blockade of CXCR3 reverses tumour growth restriction by IAV infection. by Philine Steinbach (17847521)

Expression of MMP9 in control and cystic Nek8^jck (jck) kidneys. by Nabila Djaziri (17537499)

AzEvC10 mutant hypervirulence is caused by an RNase E mutation. by Mylene Vaillancourt (7409486)

The AzEvC10 mutant induces iron dysregulation, oxidative stress, and ferroptosis in macrophages. by Mylene Vaillancourt (7409486)

Heatmaps with different genetic linkage and migration rate. by Georg Oberhofer (3401438)

“…<p>Heatmaps showing the average <i>Rescue</i> frequency for 100 <b>(A-C)</b> and 300 generations <b>(D-F)</b>. …”

Effects of heterogeneity and noise on homeostatic stability of a network. by Daniel Harnack (501634)

“…The curve represents the mean maximal recurrence allowed to ensure a stable system. It decreases with heterogeneity. …”

Behavior of a dynamic cytoskeleton under shear flow. by Thomas G. Fai (4500571)

“…<p>(a) <i>I</i>₂/<i>I</i>₁ over time for <i>k</i>_off = 0, 10, and 100 s⁻¹, (b) The lower effective shear modulus for a dynamic network leads to a higher dimensionless capillary number and greater deformations, as evidenced by the greater maximum value of <i>I</i>₁ for the network with the fastest rate of remodeling, (c) The total number of irreversibly broken edges is plotted versus time. …”

ecAT3.10 detects nucleotide-stimulated release of ATP from cells. by Jason M. Conley (3697768)

“…<p>(A) A biphasic response was apparent on average when 100 μM ATP was added at time = 30 minutes to the static bath of ecAT3.10-expressing Neuro2A cells. …”

Age at puberty and risk of asthma: A Mendelian randomisation study by Cosetta Minelli (38846)

“…Age at menarche, recorded in years, was categorised as early (<12), normal (12–14), or late (>14); age at voice breaking was recorded and analysed as early (younger than average), normal (about average age), or late (older than average). In females, we found evidence for a causal effect of pubertal timing on asthma, with an 8% increase in asthma risk for early menarche (odds ratio [OR] 1.08; 95% CI 1.04 to 1.12; <i>p =</i> 8.7 × 10⁻⁵) and an 8% decrease for late menarche (OR 0.92; 95% CI 0.89 to 0.97; <i>p =</i> 3.4 × 10⁻⁴), suggesting a continuous protective effect of increasing age at puberty. …”

Involvement of p38MAPK activation in IL-17A-mediated hypercontractility in primary cultured murine SI SMCs. by Hirotada Akiho (559455)

“…SB203580 (SB, 1 µM), BIRB796 (BIRB, 10 nM), SP600125 (JNK II, 100 nM) and JNK inhibitor III (JNK III, 100 nM) were added 15 min before addition of IL-17A (50 ng/ml). …”

Adenosine stimulates chloride conductance through the A_2B adenosine receptor (A_2BAR). by Sammeta V. Raju (329016)

“…<p>The air-liquid interface cultures of Calu-3 cells were stimulated with 100 µM of apical adenosine, followed by apical addition of 50 µM of alloxazine, a specific inhibitor for A_2BAR. …”

Accumulation of dead cells in a colonic crypt culture. by Isabella Dotti (5877590)

“…<p>The viability of a crypt culture rapidly decreases over time due to the release of dead cells and debris into the lumen. …”